On Wednesday, Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s shares inclined 10.34% to $2.24.
Actinium Pharmaceuticals Inc (ATNM) declared the closing of its formerly declared registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company’s common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost.
Actinium anticipates using the net proceeds for general corporate purposes, counting capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products comprise Actimab-A, an antibody-drug construct, which comprises monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML).
Relypsa Inc (NASDAQ:RLYP)’s shares gained 3.63% to $26.82.
Relypsa, Inc. (RLYP), a biopharmaceutical company, recently stated financial results for the quarter ended June 30, 2015. Net loss for the second quarter 2015 was $39.3 million, or $0.95 per share, contrast to $16.7 million, or $0.51 per share, for the comparable period in 2014.
Cash, cash equivalents and short-term investments totaled $299.0 million at June 30, 2015, contrast to $135.8 million at December 31, 2014. Shares outstanding as of June 30, 2015 were 41.6 million.
Research and development expenses for the second quarter of 2015 were $18.6 million, contrast to $11.1 million for the comparable period in 2014. The enhance was primarily driven by enhances in personnel expenses and manufacturing activities.
Relypsa, Inc., a biopharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. Its lead product candidate comprises Patiromer, a non-absorbed potassium binding polymer that accomplished Phase III clinical trial for the treatment of hyperkalemia.
At the end of Wednesday’s trade, Planet Payment Inc(NASDAQ:PLPM)‘s shares surged 4.01% to $3.11.
Planet Payment, Inc. (PLPM) a leading provider of international payment and transaction processing and multi-currency processing services, is happy to declare that the Company has designated Robert J. Cox as President of the Company with immediate effect. Mr. Cox will also continue in his role as Chief Operating Officer. The Company has promoted Raymond D’Aponte to Chief Financial Officer. Mr. Cox and Mr. D’Aponte will both be reporting to Carl J. Williams, Chairman and CEO.
Mr. Cox has served as our Senior Vice President, Chief Financial Officer and Treasurer since November 2009, and has served as our Chief Operating Officer since January 2014. From June 2009 to November 2009, Mr. Cox served as the Chief Financial Officer of Harris Interactive, Inc., a market research firm. From 2001 to May 2009, Mr. Cox served as the Chief Financial Officer of DealerTrack Holdings, Inc., an automotive retail software solution provider. He began his career as a Certified Public Accountant in the audit practice at KPMG LLP. Mr. Cox holds a B.A. in Accounting from St. Bonaventure University and an M.B.A. from Columbia Business School.
Planet Payment, Inc. provides international payment, transaction, and multi-currency processing services. The company offers payment processing services that enable the authorization and settlement of payment transactions by providing the connections between the merchant, its bank, and the card association; online access to advanced reconciliation and reporting services, in addition to localized language support to its customers; and multi-currency processing services, comprising of Pay In Your Currency, Shop In Your Currency, and Bank In Your Currency, in addition to multi-currency processing services designed for payment environments, customer-facing terminals, integrated front-desk systems, ATMs, and online e-commerce gateway or a third-party e-commerce gateway.
Amplify Snack Brands Inc (NYSE:BETR), ended its Wednesday’s trading session with -4.43% loss, and closed at $15.33.
Amplify Snack Brands, Inc. (BETR) declared the closing of its initial public offering of 15,000,000 shares of common stock.
All shares were sold by existing stockholders, counting certain directors and officers of the Company. Amplify did not receive any of the proceeds from the offering.
Goldman, Sachs & Co., Jefferies, Credit Suisse and SunTrust Robinson Humphrey acted as joint book-running managers for the offering. William Blair and Piper Jaffray acted as co-managers.
Amplify Snack Brands, Inc. operates as a snack food company. It produces and delivers popcorn in various flavors, counting original, black pepper, white cheddar flavor, and naturally sweet, in addition to occasional rotational and Hatch Chile flavors under the SkinnyPop; and tortilla chips in original delights, cowboy ranch, roasted jalapeno, grilled habanero, very verde good, and haunted ghost pepper flavors under the Paqui brand.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
